Search

Displaying results 2501 - 2510 of 6830 in total
  1. Drug

    Isotretinoin

    go.drugbank.com/drugs/DB00982
    ApprovedInvestigational

    Isotretinoin is a retinoid derivative of vitamin A used in the treatment of severe recalcitrant acne.[Label] It was most widely marketed under the brand name Accutane, which has since been discontinued. Isotretinoin is associated with ma...

  2. Drug

    Lurasidone

    go.drugbank.com/drugs/DB08815
    ApprovedInvestigational

    Lurasidone is an atypical antipsychotic developed by Dainippon Sumitomo Pharma. It was approved by the U.S.

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
  3. Drug

    Arimoclomol

    go.drugbank.com/drugs/DB05025
    Approved

    [L51384] Arimoclomol was approved by the FDA on September 20, 2024, making it the first treatment for Niemann-Pick disease, type C (NPC). … Arimoclomol is a hydroxylamine derivative [A264414] and a heat-shock protein-70 (HSP70) co-inducer.

  4. Drug

    Pinacidil

    go.drugbank.com/drugs/DB06762
    Approved

    Pinacidil is a cyanoguanidine drug that acts by opening ATP-sensitive potassium channels, leading to peripheral vasodilatation of arterioles and decreasing peripheral vascular resistance. … This drug has been discontinued by the FDA.

  5. Drug

    Garadacimab

    go.drugbank.com/drugs/DB15629
    Approved

    [L53303,L53283] It is the first inhibitor of factor XIIa to receive market approval.[L53303] … [A273993] In June 2025, garadacimab was approved by the US FDA for the prophylaxis of HAE episodes in patients ≥12 years of age.

  6. Drug

    Sulfapyridine

    go.drugbank.com/drugs/DB00891
    ApprovedWithdrawn

    Antibacterial, potentially toxic, and previously used to treat certain skin diseases. No longer prescribed.

  7. Drug

    Vimseltinib

    go.drugbank.com/drugs/DB17520
    ApprovedInvestigational

    [A265035] It is intended to provide a safer alternative to [pexidartinib], a previously approved CSF1R inhibitor associated with significant liver toxicity - the greater selectivity of vimseltinib results … [L52230,A265035] Vimseltinib - under the brand name Romvimza - was approved by the FDA in February 2025 for the treatment of tenosynovial giant cell tumours for which surgical resection is not appropriate

  8. Drug

    Rabeprazole

    go.drugbank.com/drugs/DB01129
    ApprovedInvestigational

    Rabeprazole is an antiulcer drug in the class of proton pump inhibitors. It is a prodrug - in the acid environment of the parietal cells it turns into active sulphenamide form. Rabeprazole inhibits the H+, K+ATPase of the coating gastric...

    Mixtures: RASOFORCE 20/1680 MG TOZ İÇEREN SAŞE, 14 SAŞE, RASOFORCE 20/1680 MG TOZ İÇEREN SAŞE, 28 SAŞE
  9. Drug

    Rubidium Rb-82

    go.drugbank.com/drugs/DB09479
    ApprovedInvestigational

    It is indicated for Positron Emission Tomography (PET) imaging of the myocardium under rest or pharmacologic stress conditions to evaluate regional myocardial perfusion in adult patients with suspected

  10. Drug

    Loratadine

    go.drugbank.com/drugs/DB00455
    ApprovedInvestigational

    Loratadine is a second generation antihistamine used to manage symptoms of allergic rhinitis.